Literature DB >> 26320099

How should we assess the value of innovative drugs in oncology? Lessons from cost-effectiveness analyses.

Vinay Prasad1, Sham Mailankody2.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 26320099      PMCID： PMC4600021          DOI： 10.1182/blood-2015-07-657478

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  6 in total

1.  Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.

Authors:  Christian Asseburg; Martin Frank; Claus-Henning Köhne; Jörg Thomas Hartmann; Ingolf Griebsch; Andrea Mohr; Ulrike Osowski; Jeltje Schulten; Thomas Mittendorf
Journal:  Clin Ther       Date:  2011-04       Impact factor: 3.393

Review 2.  Bias in published cost effectiveness studies: systematic review.

Authors:  Chaim M Bell; David R Urbach; Joel G Ray; Ahmed Bayoumi; Allison B Rosen; Dan Greenberg; Peter J Neumann
Journal:  BMJ       Date:  2006-02-22

3.  Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial.

Authors:  Marinus H J van Oers; Richard Klasa; Robert E Marcus; Max Wolf; Eva Kimby; Randy D Gascoyne; Andrew Jack; Mars Van't Veer; Andrej Vranovsky; Harald Holte; Martine van Glabbeke; Ivana Teodorovic; Cynthia Rozewicz; Anton Hagenbeek
Journal:  Blood       Date:  2006-07-27       Impact factor: 22.113

Review 4.  Value of innovation in hematologic malignancies: a systematic review of published cost-effectiveness analyses.

Authors:  Cayla J Saret; Aaron N Winn; Gunjan Shah; Susan K Parsons; Pei-Jung Lin; Joshua T Cohen; Peter J Neumann
Journal:  Blood       Date:  2015-02-05       Impact factor: 22.113

5.  Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study.

Authors:  Marinus H J van Oers; Martine Van Glabbeke; Livia Giurgea; Richard Klasa; Robert E Marcus; Max Wolf; Eva Kimby; Mars van t Veer; Andrej Vranovsky; Harald Holte; Anton Hagenbeek
Journal:  J Clin Oncol       Date:  2010-05-03       Impact factor: 44.544

6.  Cost-effectiveness of extended adjuvant rituximab for US patients aged 65-70 years with follicular lymphoma in second remission.

Authors:  John W Hayslip; Kit N Simpson
Journal:  Clin Lymphoma Myeloma       Date:  2008-06
  6 in total
  4 in total

Review 1.  Cancer drug development: The missing links.

Authors:  Ajaikumar B Kunnumakkara; Devivasha Bordoloi; Bethsebie Lalduhsaki Sailo; Nand Kishor Roy; Krishan Kumar Thakur; Kishore Banik; Mehdi Shakibaei; Subash C Gupta; Bharat B Aggarwal
Journal:  Exp Biol Med (Maywood)       Date:  2019-04-08

2.  The economic impact of the transition from branded to generic oncology drugs.

Authors:  W Y Cheung; E A Kornelsen; N Mittmann; N B Leighl; M Cheung; K K Chan; P A Bradbury; R C H Ng; B E Chen; K Ding; J L Pater; D Tu; A E Hay
Journal:  Curr Oncol       Date:  2019-04-01       Impact factor: 3.677

3.  Treatment of newly diagnosed myeloma: Bortezomib-based triplet.

Authors:  Archana M Rajan; S Vincent Rajkumar
Journal:  Semin Oncol       Date:  2016-11-05       Impact factor: 4.929

Review 4.  The high price of anticancer drugs: origins, implications, barriers, solutions.

Authors:  Vinay Prasad; Kevin De Jesús; Sham Mailankody
Journal:  Nat Rev Clin Oncol       Date:  2017-03-14       Impact factor: 66.675
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.